1064 Characterization of preclinical anti-tumor and pharmacodynamic activity in response to conditionally active IFNa with or without checkpoint blockade

• Alexey Berezhnoy,
• Michael Winter,
• Hsin Wang,
• Nicole Lapuyade,
• Madan Paidhungat,
• Dylan Daniel,
• Marcia Belvin,
• Erwan Le Scolan,
• Carol LePage,
• Leila Boustany,
• Benjamin Povinelli,
• Kamaljeet Kaur,
• Olga Vasiljeva,
• Vangipuram Rangan

Affiliations

Alexey Berezhnoy

MacrGenics, Inc., Rockville, MD, USA

Michael Winter

deputy director

Hsin Wang

CytomX Therapeutics, South San Francisco, CA, United States

Nicole Lapuyade

CytomX Therapeutics, South San Francisco, CA, United States

Madan Paidhungat

CytoX Therapeutics, South San Francisco, CA, USA

Dylan Daniel

CytomX Therapeutics, South San Francisco, CA, United States

Marcia Belvin

CytomX Therapeutics, South San Francisco, CA, United States

Erwan Le Scolan

CytoX Therapeutics, South San Francisco, CA, USA

Carol LePage

CytoX Therapeutics, South San Francisco, CA, USA

Leila Boustany

CytoX Therapeutics, South San Francisco, CA, USA

Benjamin Povinelli

CytoX Therapeutics, South San Francisco, CA, USA

Kamaljeet Kaur

CytoX Therapeutics, South San Francisco, CA, USA

Olga Vasiljeva

CytoX Therapeutics, South San Francisco, CA, USA

Vangipuram Rangan

CytoX Therapeutics, South San Francisco, CA, USA